Published in

Wiley, Australasian Journal of Dermatology, 4(64), p. 488-496, 2023

DOI: 10.1111/ajd.14140

Links

Tools

Export citation

Search in Google Scholar

Survival outcomes of head and neck melanoma patients in Queensland, Australia from 2009 to 2018

Journal article published in 2023 by Nikhil Dwivedi ORCID, Ramez Barsoum, Julie Moore, Evelyne Rathbone ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractBackground/ObjectivesTo compare survival outcomes for patients with cutaneous invasive head and neck melanoma (HNM) with those of patients with melanoma on other anatomical sites.MethodsRetrospective cohort study using patient data extracted from the Cancer Alliance Queensland's Oncology Analysis System (OASYS) over a 10‐year period from 2009 to 2018. Melanoma‐specific survival was compared between patients with HNM and non‐HNM. Kaplan–Meier survival estimates were calculated at 5 and 10 years. Univariable and multivariable Cox proportional hazards regression analysis determined factors associated with survival.ResultsThe 5‐ and 10‐year survival probabilities were 90.7% and 89.1%, respectively for HNM, compared with 94.7% and 93.0%, respectively, for non‐HNM melanoma. The 5‐ and 10‐year survival probabilities for scalp melanoma were 77.8% and 75.5%, respectively. Patients with HNM died of melanoma at 1.22 times (HR 1.22, 95% CI 1.09–1.37) the rate of those with non‐HNM, controlling for sex, age, socioeconomic status, remoteness, Breslow thickness, the presence of multiple invasion melanoma and ulceration. Patients with scalp melanoma died of melanoma at 1.57 times (HR 1.57, 95% CI 1.26–1.95) the rate of those with non‐scalp HNM.ConclusionsThere is a statistically significant survival difference between patients with HNM and non‐HNM, and between patients with scalp melanoma and non‐scalp HNM, even after adjusting for prognostic factors.